Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course

Indian Firm Awaiting Market To Open Up In FY2025

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.

Things may be looking up in the US for adalimumab biosimilars, but Coherus BioSciences, Inc.'s decision to divest Yusimry (adalimumab-aqvh) saw analysts raise questions on the wider prospects for rivals to AbbVie Inc.’s Humira in an intensely competitive segment.

India's Biocon, Ltd., for one, believes things are playing out along expected lines and doesn’t see the Humira biosimilars...